Skip navigation

Strategies to Effectively Scale the Business and Best Practices for Accounting and Reporting

September 25-26, 2018
  • Boston, MA

CBI’s Annual Finance & Accounting for Bioscience Companies convenes professionals from growing, innovative life sciences organizations to discuss strategies to implement scalable financial reporting process, mitigate risk and develop lean and efficient finance teams. This meeting hones-in on the unique challenges faced by small and mid-sized biotechs and pharmaceutical companies as they transition from private to public, enter into collaborations, cultivate talent and recognize revenue. Gain strategies to ensure regulatory compliance, train new team members, implement systems and effectively communicate financial performance.

Highlights for 2018 Include:

  • Update on FASB standards
  • Assessment of Tax reform and impact to biotech and pharma
  • Insight on financial systems, software and processes to
    gain efficiencies and effectiveness
  • Strategies for R&D collaborations and licensing deals
  • Case studies illustrating high growth and scalability of
    emerging biotech companies
  • Best practices for recruiting and retaining top talent and
    technical expertise
  • Networking opportunities with elite speakers and
    industry thought leaders

Previous Attendee Acclaim:

Time after time CBI delivers relevant and
timely content specific to our industry.

David Lowrance, Chief Financial Officer, Savara

The topics are very relevant to the life science industry.

Thomas Hess, CFO, Genomind

CBI continues to provide high class,
highly relevant and useful conferences.

Bill Steinkrauss Corporate Contoller and Director of Finance, Curis Inc.

New accounting issues — leases and rev rec —
helped point me in right direction.

Mary Phelan, Controller, Edenbridge Pharmaceuticals

Great attendees and relevant topics! Good balance
of technical and non-technical issues.

David Lewin, Managing Director, cbiz

Wonderful conference content! Very helpful and
speakers were very accessible.

Nancy Dong, VP of Finance and Administration, Contrafect Corporation